Eiger BioPharmaceuticals Announces New HCV Synergy Data

Publication describes high level of synergy of clemizole with protease inhibitor class

PALO ALTO, California, July 1, 2010 – Eiger BioPharmaceuticals, Inc., a biotechnology company developing
antiviral therapies, announced today the publication of research from the lab
of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and
colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA [...]